Eton Pharmaceuticals Files 8‑K: Submits Prior Approval to Expand KHINDIVI Indication

What Happened

• Eton Pharmaceuticals announced on July 29, 2026 that it submitted a prior approval supplement to expand the indication for KHINDIVI® (hydrocortisone) oral solution. The announcement was made via a press release attached to the Form 8‑K.

Key Details

• Filing date: July 29, 2026 (Form 8‑K, Item 8.01).
• Product: KHINDIVI® (hydrocortisone) oral solution.
• Action: Submission of a prior approval supplement to expand the product's indication.
• Exhibit: Press release dated July 29, 2026 is attached as Exhibit 99.1 to the 8‑K.

Why It Matters

• Expanding an approved indication can allow a drug to be marketed for additional uses or patient groups; if the supplement is approved, KHINDIVI's addressable market could broaden, which may affect future sales. Approval is required before any change in labeling or promotion can occur. Investors should watch for follow‑up regulatory updates and company disclosures for timing and potential commercial impact.